<DOC>
	<DOCNO>NCT00471471</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill tumor cell . Giving vaccine therapy together GM-CSF , CpG 7909 , incomplete Freund 's adjuvant may make strong immune response kill tumor cell . PURPOSE : This clinical trial study side effect well vaccine therapy work treat patient recurrent stage III stage IV melanoma remove surgery .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Recurrent Stage III Stage IV Melanoma That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety peptide vaccine comprise MART-1:27-35 peptide , gp100:209-217 ( 210M ) peptide , tyrosinase peptide sargramostim ( GM-CSF ) CpG 7909 emulsify incomplete Freund 's adjuvant patient unresectable recurrent stage III IV melanoma . - Determine efficacy immunoadjuvants CpG 7909 GM-CSF , term strong antigen-specific CD8+ T-cell response , patient . - Determine anti-pigmentary response regimen patient . - Determine anti-tumor response , term objective tumor regression , progression-free survival , overall survival , patient treat regimen . OUTLINE : This pilot study . Patients receive peptide vaccine comprise MART-1:27-35 peptide , gp100:209-217 ( 210M ) peptide , tyrosinase peptide sargramostim ( GM-CSF ) CpG 7909 emulsify incomplete Freund 's adjuvant subcutaneously day 1 15 . Treatment repeat every 28 day 13 course absence disease progression unacceptable toxicity . Blood sample collect baseline , day 50-53 , day 91-94 . Samples examine ELISPOT assay measure lymphocyte immune response flow cytometry biomarker quantification T-cell response . After completion study treatment , patient follow periodically least 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Conjunctival Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma meeting follow criterion : Unresectable recurrent disease Stage III IV disease Cutaneous , ocular , mucosal melanoma Measurable disease define RECIST criterion HLAA2 positive Prior brain metastasis allow provided adequate surgical radiologic treatment brain disease PATIENT CHARACTERISTICS : ECOG performance status 0 1 WBC ≥ 3,000/mm³ Lymphocytes ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN AST ALT ≤ 2.5 time ULN Lactic dehydrogenase ≤ 2.0 time ULN aPTT &lt; 40 second Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 1 week , , ≥ 2 week completion study therapy No condition immunosuppression Negative titer antinuclear antibody ( ≤ 1/80 ) antidouble strand DNA ( ≤ 1/10 ) No serious illness include , limited , follow : Bleeding disorder Autoimmune disease Severe obstructive restrictive pulmonary disease Active systemic infection Inflammatory bowel disorder No serious cardiovascular disease include , limited , follow : Uncontrolled congestive heart failure Hypertension Cardiac ischemia Myocardial infarction , Severe cardiac arrhythmia HIV1 2 negative HTLV1 negative Hepatitis B C negative No significant psychiatric disease , medical intervention , condition , opinion principal investigator , would limit study compliance No active infection within past week , include unexplained fever ( temperature &gt; 38.1°C ) PRIOR CONCURRENT THERAPY : Fully recover prior major surgery More 4 week since prior chemotherapy ( 6 week mitomycin C nitrosoureas ) , hormonal therapy , radiotherapy , biological therapy More 1 week since prior antibiotic More 28 day since prior investigational agent No prior vaccination MART1 ( 2635 , 27L ) , gp100 ( 209217 , 210M ) , tyrosinase ( 368376 , 370D ) peptide alone combination Patients history vaccination peptide MART1 ( 2635 , 27L ) , gp100 ( 209217 , 210M ) , tyrosinase ( 368376 , 370D ) peptide allow More 4 week since prior concurrent systemic immunosuppressive therapy , include steroid Patients maintenance steroid give physiologic dos adrenal insufficiency eligible More 2 week since prior concurrent treatment systemic steroid , include oral steroid , continuous use topical steroid cream ointment , inhale steroid No concurrent anticoagulant , except keep indwell line patent No concurrent anticancer therapy , include chemotherapy , immunotherapy , radiotherapy , experimental program , and/or surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>metastatic intraocular melanoma</keyword>
	<keyword>conjunctival melanoma</keyword>
	<keyword>stage IIIA melanoma</keyword>
	<keyword>stage IIIB melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
</DOC>